| Safeway Pharmacy #1966 | |
| 13101 Se Kent Kangley Road, Kent, Washington 98030 | |
| (253) 638-0831 |
| Name | Safeway Pharmacy #1966 |
|---|---|
| Organization Name | Safeway Inc |
| Location | 13101 Se Kent Kangley Road, Kent, Washington 98030 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (253) 638-0831 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.
The DSF Charitable Foundation has given a $3.9 million grant to Carnegie Mellon University's Center for Nucleic Acids Science and Technology to further the development of novel biomedical tools targeted at monitoring and manipulating gene expression.
Researchers say these findings highlight the need for improved diagnosis and treatment of sleep disorders in mild traumatic brain injury patients who complain of insomnia.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
› Verified 5 days ago
| NPI Number | 1598794521 |
| Organization Name | SAFEWAY INC |
| Doing Business As | SAFEWAY PHARMACY #1966 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 13101 Se Kent Kangley Rd, Kent, WA 98030 |
| Phone Number | 253-638-0831 |
News Archive
Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.
The DSF Charitable Foundation has given a $3.9 million grant to Carnegie Mellon University's Center for Nucleic Acids Science and Technology to further the development of novel biomedical tools targeted at monitoring and manipulating gene expression.
Researchers say these findings highlight the need for improved diagnosis and treatment of sleep disorders in mild traumatic brain injury patients who complain of insomnia.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
› Verified 5 days ago
News Archive
Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.
The DSF Charitable Foundation has given a $3.9 million grant to Carnegie Mellon University's Center for Nucleic Acids Science and Technology to further the development of novel biomedical tools targeted at monitoring and manipulating gene expression.
Researchers say these findings highlight the need for improved diagnosis and treatment of sleep disorders in mild traumatic brain injury patients who complain of insomnia.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
› Verified 5 days ago
Accredo Health Group Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 22623 68th Ave S, Kent, Washington 98032 Phone: (253) 872-2121 | |
Breg, Inc. Type: Durable Medical Equipment & Medical Supplies Supplier Location: 25528 74th Ave S, Kent, Washington 98032 Phone: (253) 859-7791 | |
Fred Meyer Pharmacy Type: Durable Medical Equipment & Medical Supplies Supplier Location: 16735 Se 272nd Street, Kent, Washington 98042 Phone: (253) 639-7433 | |
Fred Meyer Pharmacy #172 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 10201se240th St, Kent, Washington 98031 Phone: (253) 859-5533 | |
Fred Meyer Pharmacy #215 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 25250 Pacific Hwy S, Kent, Washington 98032 Phone: (253) 946-7433 |